MedTrace Logo

MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer

NCT02735512 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2022-08-10

No results posted yet for this study

Summary

This pilot research trial studies how well myeloid derived suppressor cells (MDSC) clinical assay works in finding and monitoring cancer cells in blood and urine samples from patients with or without localized or metastatic bladder cancer. Studying samples of blood and urine from patients with or without bladder cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer and may help doctors improve ways to diagnose and treat patients.

Conditions

  • No Evidence of Disease
  • Stage II Bladder Cancer
  • Stage III Bladder Cancer
  • Stage IVA Bladder Cancer
  • Stage IVB Bladder Cancer

Interventions

OTHER

Cytology Specimen Collection Procedure

Undergo collection of blood and urine samples

OTHER

Laboratory Biomarker Analysis

Samples undergo MDSC clinical assay

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Jacek Pinski · University of Southern California

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2022-04-13
Completion
2022-04-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02735512 on ClinicalTrials.gov